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Abstract
In this paper, we evaluate nuclear medicine tests used for the
diagnosis of breast carcinoma. Breast carcinoma is the most
common carcinoma in women in Europe and its early diagno-
sis and treatment is important for the overall survival of the pa-
tients. Scintimammography technique, indications, contraindi-
cations and diagnostic procedures for the identification of the
sentinel node and the axillary nodes infiltrated by tumour are
described. Also, the use of the radiopharmaceuticals, radioac-
tive thallium chloride-201, methylene diphosphonate labelled
with technetium-99m, somatostatin receptors labelled with in-
dium-111, diagnostic procedures with the PET camera, the la-
belled antibodies to CEA with technetium-99m and also the
importance of the MRI and the US techniques are mentioned.
These tests have greater diagnostic accuracy as compared to
X-ray mammography, clinical examination, MRI and the US tech-
nique. Tumour markers in vitro are recommended for the fol-
low-up of metastatic breast carcinoma.
Key words: breast carcinoma, scintimammography,
lymphoscintigraphy, 99mTc-sestamibi, 99mTc-tetrophosmin
Introduction
Breast carcinoma (BC) is the most common carcinoma in
women in Europe [1]. Nuclear Medicine (NM) has an important
contribution both to the diagnosis and to the differential diagnosis
of BC. It is known that the correct initial diagnosis permits progress
to a successful treatment of BC. Unfortunately, at  present, the
correct diagnostic and therapeutic procedures are a matter of dis-
cussion. Questions like these that follow arise: Are X-ray mam-
mography and physical examination enough to diagnose BC?
What is the place of scintimammography (SM), sentinel node (SN)
scintiscan, magnetic resonance imaging (MRI), ultrasound (US)
for the diagnosis of BC? What are the future prospects of using
whole body scintiscans imaging somatostatin receptors? Can tu-
mour markers and positron emission tomography (PET) proce-
dures contribute to the diagnosis of BC? How shall we reduce the
discomfort of performing some of the diagnostic procedures? And
the most important question of all: Can we increase the survival of
patients suffering from BC?
In the present paper, we will discuss the contribution of NM in
the early diagnosis of BC compared to other diagnostic techniques.
While describing and supporting our points of view, we will take
into consideration the opinions of others, published during the
last seven years.
From the total range of NM techniques, we will describe the
following: a) SM; b) the search for SN; c) the routine bone scan d)
the PET test e) specific whole body scintiscan; f) the MRI test and
g) tumour markers as in vitro tests.
Scintimammography
Scintimammography is the imaging of breast tumours by
a special technique of NM. The first description of the SM tech-
nique was in 1987. Since then, considerable progress has been
made. The most commonly used radiopharmaceuticals with
a SPET camera are: a) exakis-2-methoxy-isobutil-isonitril labelled
with 99mTc (99mTc-MIBI or sestamibi); b) tetrophosmin labelled with
99mTc (99mTc-tetrophosmin or myoview); c) radioactive thallium
chloride-201 (201TlCl) and d) methoxy-phosphonic technetium-99m
(99mTc-MDP). The first two of the above mentioned radiopharma-
ceuticals are taken up by the cancer cells of the breast, 4–8 times
more than from normal cells [1]. This takes place because cancer
cells have an increased function in their mitochondria which means
that they accept larger quantities of the two first radiopharmaceu-
ticals [2, 3]. Cancer cells have increased turnover of potassium
and so they take up larger quantities of thallium-201. Cancer cells
also have increased turnover for phosphate and thus take up larger
quantities of 99mTc-MDP. In contrast, benign tumours (adenomas,
cysts, some chronic inflammatory lesions) are very slightly im-
aged or not at all by the above radiopharmaceuticals.
According to some writers, malignant tumours of the breast
are better imaged in the late images while adenomas and inflam-
matory tumours are better seen in the early images. In order to
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evaluate the latter finding, the difference in the intensity of the im-
ages should be clear and the images should be acquired under
similar conditions [4]. The duration of acquisition for early images
may vary from 5 to 10 min [5].
Indications: SM is recommended to women, older than 21,
not pregnant, not lactating, with a clinically palpable nodular mass
in their breast and a doubtful X-ray mammography [6]. Also, SM
is recommended in order to discern the existence of local cancer-
ous lymph nodes when the tumour markers in vitro are positive,
even if we do not palpate a tumour and in order to choose the
best treatment schedule and to follow up the efficacy of treat-
ment. The above mentioned indications for applying SM are rein-
forced in the case where the woman examined has a family histo-
ry of breast carcinoma or is a carrier of the BCL2 genetic index
[7]. The patient should be thoroughly informed about the kind and
importance of the examination and agree to undergo it [6].
Scientimammography is not recommended in the case of
preexisting partial mastectomy because false positive signs due
to surgery may appear. Also, SM is not indicated in the case of
a thin needle biopsy performed within the previous week because
the local haemorrhage from the puncture can result in a false neg-
ative image. Finally, SM is not recommended after scintigraphy
with some other radionuclide if 10 halflives of this radiopharma-
ceutical have not elapsed. Otherwise we may have false positive
findings [6].
The technique of SM is as follows [4]: about 740 MBq (660–
–1110 MBq) of 99mTc-sestamibi is injected intravenously. A spe-
cially adapted bed is used so that the breast, when the patient is
in prone position, hangs downwards and thus the image of the
heart and liver are separated (Fig. 1). Early images are acquired
at 10–15 min post injection. The breast is scintiscanned in supine,
lateral and oblique positions. At 45–60 min post injection the so-
called late image is acquired. The radiopharmaceutical is prepared
by the radiophysicist or a trained technologist under the radio-
physicist’s supervision, as follows: the stable substance in pow-
der is contained in a sterilised vial with a capacity of about 20 ml.
A solution of the radionuclide Na2
99mTcO4 is added to the vial and
the whole is warmed in a waterbath. In the end, the purity of the
complex radiopharmaceutical should not be less than 90%. This
is tested by chromatography. Otherwise, the whole is rejected.
The above used radiopharmaceuticals are normally retained,
mainly in the myocardium, the liver, the spleen, the thyroid and
the salivary glands, while they are excreted mainly through the
liver and the biliary system.
When SM is done not by the planar but by the tomographic
g-camera, SPET and by the use of the radiopharmaceutical 99mTc-
-sestamibi, the sensitivity of the test is increased by 30%, without
an increase in its specificity [8]. The accuracy of the diagnosis
with the above mentioned radiopharmaceutical and the planar
camera is slightly higher than that of the X-ray mammography,
regarding tumours located inside the breast [9]. The above tech-
nique is characterised by diagnostic accuracy, specificity and
sensitivity higher than 95% [11]; in multicellular breast cystic ade-
nomas it is often false positive [10]. It is worth mentioning that the
cancerous tumour of patients undergoing chemotherapy, after
about 3 months of chemotherapy, absorbs almost half of the ra-
diopharmaceutical, compared to that before chemotherapy; how-
ever, this finding has no significant impact on the response of
breast cancer to chemotherapy [11].
According to a paper by colleagues from 7 European coun-
tries, who have studied 195 palpable and 58 non-palpable nodu-
lar breast lesions, when the images were being examined by nu-
clear medicine practitioners, the general sensitivity of SM was 91%
[7]. Similar sensitivity was noticed between breast cancer of the
ducts and of the gland lobes parenchyma. Tumours with a diam-
eter of 1 cm to 1.5 cm had a sensitivity of 74%. When the tumour
had a diameter of more than 1.5 cm, sensitivity increased to 95%
[6]. Generally speaking, breast tumours with a diameter of less
than 1 cm are not evaluated. The specificity of diagnosis with SM,
which depends on the kind and the size of the lesion as well as on
the evaluation of the positive findings in the scintiscan image, rang-
es from 70–81% [6]. In general, according to multi-centre studies
in Europe, Canada and the USA, SM sensitivity regarding palpa-
ble breast lesions reaches 95% [6, 12]. The above figures show
that the positive “warm” images of lesions in palpable breast tu-
mours with a diameter bigger than 1.5 cm can distinguish carci-
nomas from benign lesions, up to a percentage of 95%. On the
whole, SM is more trustworthy when a lesion is diagnosed as non-
cancerous. The above mentioned refer to studies where the ra-
diopharmaceutical 99mTc-sestamibi was used.
As regards the other radiopharmaceutical used in SM, that is
99mTc-myoview or tetrophosmin, cancerous cells absorb it in the
same manner as 99mTc-sestamibi but this radiopharmaceutical is
retained for a shorter period of time by the chromosomes. 99mTc-
-myoview SM has a sensitivity and specificity in the diagnosis of
BC higher than 90% [13–16]. A negative scintimammogram with
99mTc-sestamibi in a woman with a left mastectomy for breast car-
cinoma is shown in Figure 2. Another scintimammogram positive
for breast carcinoma is shown in Figure 3.
Compared to other diagnostic techniques, SM can detect
a cancerous lesion in the breast in the case where the X-ray mam-
mography gives doubtful results, to a percentage of 61%. For the X-
-ray mammography, the specificity is only 42%. In the case of a con-
crete tumour not palpated not shown in the X-ray mammography but
having microcalcifications, a fine needle biopsy and the surgical re-
moval of the lesion are recommended [1]. In such a case, SM is not
recommended since it cannot trace lesions like the minute infiltrat-
ing duct carcinoma which may be the cause of the above case [1].
Figure 1. The examination bed as specifically modified for scintimam-
mography. The lying level is from plexiglass and all the rest of the bed
consists of a metal frame.
Plexiglas Iron frame
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Scintimammograhy was studied using 99mTc-sestamibi in 22
palpable and 5 non palpable breast carcinoma patients in com-
parison with the X-ray mammography and MRI. SM was proven to
have a significantly better specificity in palpable (75%, 25% and
50% respectively) and in non-palpable tumours (62%, 10% and
15% respectively) [17].
Scintimammograhy results using 99mTc-tetrophosmine were
found to be similar to the above with very good diagnostic acurracy
[13, 14, 17].
The diagnosis of the sentinel node
and the axillary lymph nodes infiltrated
by tumour — lymphoscintigraphy
There has been a tendency, in recent years, to limit the extent
of surgical operations in cases of breast carcinoma [18]. These
operations aim at radically removing the carcinoma without af-
fecting the healthy tissues. According to this point of view, the
early diagnosis of the initial cancerous lesion and the nearby lymph
nodes where the lesion has probably spread, is extremely useful.
Through a special technique, NM traces the lymph nodes that are
possibly infiltrated by carcinoma and during the operation points
out the positions where metastatic cancerous tissue exists [19].
By tracing the SN, we specify the primary line of lymph flow from
the tumour. The SN may be affected by metastases. The test shows
the existence of SN but not whether it contains metastatic cells. If,
during the histological examination that will follow the removal of
the lymph node, no metastasis is found, the surgeon might avoid
the total removal of the axillar lymph nodes. Before or after the
operation, this technique can find non-palpable cancerous lesions
of BC and thus facilitate their surgical removal [19]. This test is
based on the fact that radiopharmaceuticals of a certain molecu-
lar size that are injected around or inside the initial breast carcino-
ma, are trapped in the SN. The radiopharmaceutical is injected
before, during or after the operation. We examine the lymph nodes
that absorbed the radiopharmaceutical and/or the initial tumour in
two different ways: a) With a special cylindrical probe for surface
measurements. This probe is sterilised and used even inside the
operating-theatre (counting probe) and b) Applying a scintiscan
after 10–20 min, 2 h, 6 h even after 24 h, depending on the sur-
geon’s will and injecting a higher dose of radioactivity respectively.
We use as radiopharmaceuticals: a) macroaggregates of hu-
man albumin with a molecular diameter of 10–150 µm (Macrotec,
Amersham-Sorin Co) labelled with 99mTc which more often are in-
jected inside the lesion; b) colloid particles of human albumin with
a diameter of 0.2–1.0 µm (Albures, Amersham-Sorin Co) labelled
also with 99mTc in a volume of 0.2 ml, that are injected outside but
near the tumour in order to get trapped in the SN; c) sulphur col-
loid also labelled with radioactive technetium, usually injected
outside the tumour. The above mentioned radiopharmaceuticals
are administered in a dose of 11 MBq for each primary tumour.
We believe that the two latter radiopharmaceuticals that have
a smaller molecular diameter can be injected simultaneously both
around and inside the tumour. Several variations of this technique
exist, especially in the case of more than one infusion in the area
around the tumour. We usually perform scintiscan images imme-
diately after the injection of the radiopharmaceutical in supine and
front lateral position so as to examine the axillary area too. The
head of the g-camera is placed as close to the patient’s body as
possible, while an anatomic marker of 57Co is placed on her skin.
This marker may be solid or liquid containing 57Co. As a linear
anatomic marker we may use a thin flexible tube containing the
Figure 3. In the scintimammography performed with 99mTc-sestamibi, two
breast lesions due to ductal carcinoma are seen at the lower part of the
right breast. Microcalcifications were seen in the X-ray mammography.
Figure 2. A 53-year-old patient with breast carcinoma and left mastectomy
a year ago. Because of pain in her right breast, she had an X-ray mam-
mography with a doubtful result. Scintimammography with 99mTc-sestamibi
followed which was clearly negative. The patient is well 3 years later.
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same radiopharmaceutical. Thus, the limits of the breast under in-
vestigation become visible especially in the lateral position [20]. The
lateral images are useful for tracing the depth of SN but also of the
initial tumour [19]. The above scintiscan is repeated after 45 min
— 3 h. This late image shows the initial tumour and the SN better,
since it has less background (bg) radiation of the surrounding tissues.
The predominant technique of breast lymphoscintigraphy,
which coincides with our observations, refers to the injection of
0.4 ml of the radiopharmaceutical with 70 MBq, divided into
4 equal doses, in the periphery of the primary tumour [5, 21]. The
hypodermic injection is not recommended. If surgical removal of
the tumour has preceded long before, the above injection is done
in the walls of the surgically created cavity. The position of the
injection, as well as the position of the SN, might be at a depth of
1 to 7 cm; so, in non-palpable lesions we might get help from an
ultrasound test in order to locate its position. For lymposcintigra-
phy, a special bed is not recommended. The patient is lying in
supine and lateral position and images are acquired at 10 min,
2 h or even 24 h. The actual surgical operation usually takes place
24 h after the injection of the radiopharmaceutical [19].
Let us point out that in surgical practice, when the palpable
breast carcinoma has a diameter of less than 1 cm, the feasibility
to cause metastases in the SN is less than 5%. As a result, the
surgical cleansing of the axillary area might not be necessary [18].
In order to determine cancer metastases surely in SN we use the
above technique. This technique has also been successfully ap-
plied in melanomas [18]. If a further biopsy of the SN is negative,
we do not proceed to sugical cleansing of the axillary area [18].
Provided that SN shows no metastases by this technique, the fine
needle biopsy in the suspected lymph nodes is avoided [18]. What
is more, the radionuclide technique determines the stage of the
cancer so as to plan the therapeutic procedure better.
Before the application of the radionuclide technique mentioned
in order to trace SN, the surgeons used an infusion of a blue pig-
ment in or around the primary tumour and searched for lymph
nodes retaining the pigment, during surgical intervention. The lat-
ter technique is successful in only 60–70% of cases [18, 19]. Some
disadvantages of the blue pigment technique are: a) the fact that
it can be used only during surgery and not before or after surgery;
b) it is difficult to find a possibly suspicious or metastatic lymph
node; c) it is unpleasant for the surgeon to use the pigment; d) the
surgeon does not know if he has removed all the lymph nodes
that contain the pigment; as a result, he is obliged to search as
much as possible by making several search incisions. In contrast,
when using the radiopharmaceutical technique that was previously
described, the technique can be applied before, during and after
surgery; in this way, we avoid all the above mentioned disadvan-
tages and increase the percentage of a successful diagnosis of
the SN to 97% [19]. According to other researchers [21], the pos-
itive and the negative values of the radionuclide technique are
100% and 96% respectively. Based on these results, certain surgi-
cal clinics do not proceed to axillary diagnostic lymphadenectomy
when the patient is in stage T1 and the SN technique is negative
[20]. Some believe the same about stage T2, when the primary
tumour is small [21].
Not finding an affected SN via the radiopharmaceutical tech-
nique clinically means that, in such a case, the 10-year survival,
compared to the one if the patient had 1–3 metastatic lymph nodes,
is increased by about 15% [20]. In case the SN is histologically
negative, yet accompanied by: a) a primary cancerous tumour
bigger than 1 cm b) a tumour that is histologically extremely ma-
lignant c) when micrometastases are found via immunohistochem-
ical techniques d) when via the chain reaction of the reverse
transpeptidase-polymerase, special cancerous genes are found,
then despite the negative SN, an international research team rec-
ommends supplementary or additional chemotherapy with or with-
out tamoxifen. This treatment is believed to increase the survival
expectancy of 10 years by around 7% [22, 23]. This percentage is
not big. Of course, the above special histopathological examina-
tions for the tracing of micrometastases in the lymph nodes are
conducted only in very few laboratories; as a result, most sur-
geons are based on the diameter of the primary tumour (> 1 cm)
and the degree of histological malignancy of the cancer in rela-
tion to the existence of oestrogen receptors and the NM tests in
order to choose the best therapeutic process. The whole issue is
still under research [22].
Diagnostic procedures with
201TICI and 99mTc-MDP
The relevant scintiscans are not used today, since these ra-
diopharmaceuticals have been replaced, because of lower diag-
nostic acurracy, by the 99mTc-sestamibi and 99mTc-tetrophosmin
mentioned above. During the usual bone scintiscan which is per-
formed with 99mTc-MDP and which is usually recommended to
women with breast carcinoma, it is better to acquire images of the
breast area in supine and lateral positions and during about 2 h
from the time of the infection, so as to obtain better information
regarding the evolution of breast carcinoma or its response to
treatment.
Diagnostic procedures with the PET camera
The diagnostic procedures with a PET camera are performed
by using positron emitting radiopharmaceuticals such as H2O [15],
18F-d-glucose etc. A comparative study, with the SPET camera
and 99mTc-sestamibi on the one hand and PET camera with
18F-d-glucose on the other, showed equal sensitivity and speci-
ficity in the diagnosis of primary breast carcinomas. However, as
regards the diagnosis of metastatic infiltration of the axillary lymph
nodes, the PET technique was better since it diagnosed 100% of
the cases, compared to 92% that the SPET technique diagnosed
[24]. The smallest lymph node depicted had a diameter of 1.2 cm.
We mention that although clinical examination and radiological
mammogram have a diagnostic accuracy of 73% and 70% re-
spectively, examination with the PET technique shows specificity
and sensitivity that exceed 90% [25]. The PET camera can trace
more small lymph nodes with a diameter of around 1 cm. We
believe that the PET technique will turn out to have even higher
specificity in diagnosis in the future [26]. The PET technique has
more advantages compared to the functional MRI (fMRI) tech-
nique because it can better examine the whole body metastases.
Besides, it has a significantly higher sensitivity and specificity as
regards the whole body bone scintiscan [27].
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We refer to the radioactive octreotide: 111In-Octreotide, which
is intravenously injected at a dose of about 220 MBq and the scin-
tiscan is performed at 4 and at 24 hours post injection. This ra-
diopharmaceutical gives better results than using as a radiophar-
maceutical 201TICI28, but not better than 99mTc-sestamibi26. Finally,
it is 3–4 times more expensive than 99mTc-sestamibi.
Diagnostic procedures with MRI and with US
This diagnostic procedure of the MRI has the disadvantage of
being difficult to perform on a large number of patients because
the relevant apparatus is not often available. It is considered to
have the same sensitivity but significantly less specificity com-
pared to SM performed with the 99mTc-sestamibi [29–31].
As for the use of US in the detection of BC, in a total of 353
female patients, US detected 70%, while SM 96% of all BC cases
[32]. US is more often recommended for disinguishing solid from
cystic masses of BC [33].
Diagnostic procedures with labelled
antibodies to CEA (CEA-Ab-99mTc)
This test can locate cancerous breast lesions or whole body
metastases but does not seem to have significantly higher spec-
ificity as regards SM performed with the 99mTc radiopharmaceuti-
cals, since its specificity reaches only 63% [34, 35].
Dosimetry
In the usual X-ray mammography, the image acquired is con-
sidered to give to the person examined 1.4 mGy in average, while
the lateral image gives 1.7 mGy [36]. From the 111 MBq 201TICI
administered for the performance of SM, a nurseling that breast-
feeds, absorbs a dose of up to 1.6 mSv [36, 37]. This dose is
significant, since the yearly allowed dose limit per adult is 1 mSv.
Generally, a dose higher than 74–111 MBq of 201TICI should not
be administered to an adult, because this radionuclide is absorbed
by the genital organs and in higher doses harms them seriously.
However, SM performed with the 99mTc radiopharmaceuticals, the
scintigraphic procedure for identifying the SN and lymphoscintig-
raphy emit smaller and permitted doses of radioactivity to the adult
patients [38, 39]. Children of up to 1 year old that breast feed,
absorb up to 0.9 mSv [38].
The techniques for tracing SN and lymphoscintigraphy emit
a minimum absorbed dose to the patient and, consequently, no
special measures of radiation protection are required [8].
The in vitro tumour markers for
the diagnosis of breast carcinoma
We refer to serum tests with radionuclides or not in patients
for tracing special anticancerous antibodies or antibodies against
the cancer-embryonic antigen (CEA). These antibodies are traced
using radioactive iodine — 125 which, in contrast to iodine-131,
has a low g radiation (35 keV) and longer half-life (60 days); for
these reasons, it is ideal for in vitro measurements of serum sam-
ples. The relevant radioimmunological techniques are the RIA and
IRMA techniques that differ since the IRMA technique is more sen-
sitive because it uses a double antibody in order to distinguish
the substance examined [37].
The tumour markers do not apply in the diagnosis of breast
carcinoma at initial stages I and II. They are used mainly for diag-
nosis in cases of wholebody metastases. In fact, we study the
changes of these markers during therapy so as to estimate their
diagnostic importance. Consequently, tumour markers are useful
as relative signs of improvement or aggravation of the metastatic
disease. Their sensitivity in the diagnosis of cancer does not ex-
ceed 70–75% [40, 41].
Apart from RIA and IRMA tests, there are also non-radionu-
clidic tests by immunoenzymatic or fluorinometric or other corre-
sponding techniques (ELISA, LIA etc). These techniques are ob-
viously less sensitive and specific as compared to the radionu-
clidic ones because they are based on photometry or fluorometry
of many relevant molecules, whereas radionuclides label and ex-
amine each molecule and measure the radioactivity they emit.
The most sensitive markers for breast carcinoma are: CA 15–3
(with two anticancerous antigens of the breast), TPA (tissue spe-
cific antigen) and CEA. At stages III and IV of breast carcinoma,
these markers have a greater sensitivity in the diagnosis of whole
body metastases compared to SM [41]. It is believed that CEA
increases 3.9 months before the clinical finding of breast carcino-
ma metastases [42]. However, we should bear in mind the great
sensitivity of the known g-glutamyl-transferase that significantly
increases in the case of liver metastases of any cause [43].
In conclusion, in the diagnosis of the first stages of breast
carcinoma, the search for SN can be performed with lymphoscin-
tigraphy and SM is recommended to support operation planning
[44]. These tests have a greater diagnostic accuracy compared
to X-ray mammography, clinical examination and MRI. Tumour
markers in vitro are recommended for the follow-up of metastatic
breast carcinoma.
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